LCTX today
$1.11+$0.07 (+6.73%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourAscending Triangle
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $1.12
Key levels
Resistance$1.19
Resistance$1.12
Support$1.06
Support$0.96
Latest news & SEC filings
NewsLineage Cell Therapeutics Gives Update on ReSonance Program Progress
NewsLineage Cell Therapeutics gives update on ReSonance hearing loss program
DealLineage Cell Therapeutics says ReSonance enters year 2 of William Demant hearing loss partnership
EarningsLineage Cell Therapeutics Discusses Q2 2026 Earnings on Conference Call
All LCTX news →About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a biotechnology company focused on creating transplantable cells to replace tissue lost or damaged by disease or injury. Its most advanced candidate, OpRegen, is being tested in mid-stage human trials with Roche and Genentech as a possible treatment for an eye condition that causes vision loss. The company also has earlier-stage programs targeting spinal cord damage, hearing problems, and diabetes-related cell loss. Manufacturing takes place at a company facility in Israel.
Based on the company's 10-K filed Mar 5, 2026.
NYSE · Healthcare
Lineage Cell Therapeutics, Inc. (LCTX)
What Is the Price Target for LCTX?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is LCTX a Buy or Sell Right Now?
Thesis
- •Revenue growing 53.2% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LCTX.
Start Free Trial →Is LCTX Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B
Fair Value
$0.60
17
Moat Score
NONE
3/9
Piotroski Score
-4.2
Altman Z-Score
What Is Smart Money Doing with LCTX?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LCTX Growth Story
Revenue YoY
53.2%
3yr Revenue CAGR
-0.3%
EPS Growth YoY
-211.11%
FCF Growth YoY
17.8%
Revenue Trend
ACCELERATING
Dark Pool Trades for LCTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LCTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:28:21 | $1.13 | 11,500 | $$13K | BUY |
| 21:49:43 | $1.13 | 2,600 | $$3K | BUY |
| 21:01:44 | $1.11 | 1,155 | $$1K | SELL |
| 21:01:42 | $1.11 | 36,131 | $$40K | SELL |
| 21:00:04 | $1.11 | 1,200 | $$1K | SELL |
5 dark pool trades shown · $$59K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Lineage Cell Therapeutics, Inc. (LCTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LCTX — frequently asked questions
What is LCTX stock price today?
Lineage Cell Therapeutics, Inc. (LCTX) is at $1.11, up 6.73% (+$0.07) at the Nov 11, 2026 close.
Why is LCTX stock moving today?
Latest LCTX news — Oct 30, 2026: Lineage Cell Therapeutics Gives Update on ReSonance Program Progress · Oct 29, 2026: Lineage Cell Therapeutics gives update on ReSonance hearing loss program
What do analysts rate LCTX?
Analyst ratings for LCTX: 6 Buy, 1 Hold, 0 Sell — consensus Strong Buy.
Did LCTX beat earnings?
LCTX last reported on Aug 6, 2026: EPS -$0.03 vs -$0.03 expected — a miss of 6.0%.
Does LCTX pay a dividend?
LCTX does not currently pay a dividend.
What are LCTX support and resistance levels?
Support: $1.06, $0.96, $0.88. Resistance: $1.12, $1.19, $1.29.
What are insiders doing with LCTX?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on LCTX?
Oct 30, 2026: Lineage Cell Therapeutics Gives Update on ReSonance Program Progress · Oct 29, 2026: Lineage Cell Therapeutics gives update on ReSonance hearing loss program · Oct 29, 2026: Lineage Cell Therapeutics says ReSonance enters year 2 of William Demant hearing loss partnership